Inflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study included patients diagnosed with IBC between 2010 and 2017 to account for advances in neoadjuvant systemic therapies and modern radiotherapy at seven oncology centres in France. Three hundred and seventeen patients were included and analysed. After a median follow-up of 52 months, the 5-year DFS was lower for triple-negative (TN) (50.1% vs. 63.6%; p < 0.0001). After multivariate analyses, incomplete nodal response was the only significant prognostic factor in the triple-negative group (HR:6.06). The poor prognosis of TN-IBC was reversed in the case of nodal response after neoadjuvant chemotherapy. Breast response does not appear to be a decisive prognostic factor in patients with TN-IBC compared to lymph node response. Despite improvements in neoadjuvant treatments, IBC remains associated with a poor prognosis. In TN-IBC patients, lack of pathological complete node response was associated with poorer survival than any other group. Treatment intensification strategies are worth investigating.
The sentinel lymph node technique is minimally invasive and used routinely by surgeons, reducing the need for morbid extensive lymph node dissections, which is a significant advantage for cancer staging and treatment decisions. The sentinel lymph node could also help radiation oncologists to identify tumor drainage for each of their patients, leading to a more personalized radiotherapy, instead of a probabilistic irradiation based on delineation atlases. The aim is both to avoid recurrence in unexpected areas and to limit the volume of irradiated healthy tissues. The aim of our study is to evaluate the impact of sentinel lymph node mapping for radiation oncologists. This concept, relying on sentinel lymph node mapping for treatment planning, is known as lymph-flow-guided radiotherapy. We present an up-to-date narrative literature review showing the potential applications of the sentinel lymph node technique for radiotherapy, as well as the limits that need to be addressed before its routine usage.
Background Immune checkpoint inhibitors (ICI) have changed cancer treatment, but they also bring a risk of immune-mediated cardiac toxicities (IMCT), such as myocarditis. Given the rarity but high mortality rates of IMCT, early detection is crucial. Objectives This study aimed to evaluate the impact of our cardiac monitoring algorithm, based on troponin and electrocardiogram follow up, on patients undergoing ICI therapy, assessing whether it reduces treatment interruptions and severe cardiac adverse events. Methods A retrospective study was conducted using data from the West Cancer Institute in Saint Herblain, France. Patients treated with ICIs for lung cancer or melanoma were divided into two groups: group A treated in 2019 (pre-algorithm) and group B treated in 2020–2021 (post-algorithm). The primary objective was to assess the impact of monitoring on the number of treatment cycles canceled or delayed. The secondary objective was to assess the rate of grade 3–4 cardiac or associated adverse events. Results 162 patients were included (45 – group A, 117 – group B). There was no significant difference in treatment interruptions (26.7% vs. 24.8%, p = 0.96). Moreover, the rate of grade 3–4 cardiac or associated adverse events was similar between the two groups (p = 0.2). Conclusions The implementation of the cardiac monitoring protocol had no negative impact on treatment administration but without reduction of severe cardiac or associated immune induced adverse event. This implementation demonstrated good adherence to the procedure; however, further efforts are needed to optimize strategies for the early detection of rare but serious adverse events.
1 June 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Brain metastases or primary brain tumours had poor prognosis until the use of high dose radiotherapy. However, radionecrosis is a complex challenge in the post-radiotherapy management of these patients due to the difficulty of distinguishing this complication from local tumour recurrence. MRI alone has a variable specificity and sensibility, as does PET-CT imaging. We aimed to investigate the diagnostic performance of dual-phase 18F-FDG PET-mpMRI to distinguish cerebral radionecrosis from local tumour recurrence after cranial radiotherapy. A retrospective analysis was conducted between May 2021 and September 2022. Inclusion criteria encompassed patients with inconclusive MRI findings post-radiotherapy and history of cerebral radiotherapy for primary or metastatic brain lesions. Lesions are assessed qualitatively and semi-quantitatively. The gold standard to assess radionecrosis was histopathology or a composite criterion at three months. The study evaluated 24 lesions in 23 patients. Qualitative analysis yielded 85.7% sensitivity and 75% specificity. Semi-quantitative analysis, based on contralateral background noise, achieved 100% sensitivity and 50% specificity. Moreover, using contralateral frontal lobe background noise resulted in higher performances with 92% sensitivity and 63% specificity. Stratification by lesion type demonstrated 100% sensitivity and specificity rates for metastatic lesions. The diagnostic performance of dual-phase 18F-FDG PET-mpMRI shows promising results for metastatic lesions.